Core Viewpoint - The announcement by the company regarding the approval of a new specification for its pulmonary arterial hypertension (PAH) treatment product, Treprostinil injection, highlights its commitment to providing precise treatment options for patients [1][2] Group 1: Product Approval and Specifications - The new specification of Treprostinil injection (20ml:50mg) has received drug registration certification from the National Medical Products Administration, complementing the previously approved specification (20ml:20mg) in March 2023 [1] - Treprostinil is a synthetic prostacyclin analog that promotes vasodilation and inhibits platelet aggregation, making it a first-line treatment for PAH and a foundational drug in targeted therapy combinations [1] Group 2: Company’s Focus and Product Pipeline - The cardiovascular emergency sector is a key focus area for the company, which has nearly 30 products in this segment, with 14 included in the national emergency rescue drug list and 16 in the shortage drug list, positioning the company among the industry leaders in product pipeline quantity [1] - The company has over 20 products under research in the cardiovascular emergency sector, including treatments for rare diseases, with recent approvals for drugs addressing high ammonia levels and Cushing's disease, and ongoing development for other rare disease medications [2]
远大医药：曲前列尼尔注射液新规格国内获批上市